Rheumatology Oxford Journal
Fecha de publicación: 1 June 2018
DOI: https://doi.org/10.1093/rheumatology/key004
Autores: Monika M Schoels, Uriel Landesmann Farideh, Alasti Daniel, Baker Josef S Smolen, Daniel Aletaha
Background: In PsA management, remission and low disease activity represent preferential treatment targets. We aimed at evaluating the predictive value and clinical use of initial therapeutic response for subsequent achievement of these targets.